Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
Oh the Places You’ll Go (with 1 billion regressions an hour) explores the partnership with Alnylam to access and understand the data from the UK Biobank project. Click the image below to view the full video: